GILD Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Company profile

Daniel O'Day
Fiscal year end
IRS number

GILD stock data



6 May 21
8 May 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 4.07B 4.07B 4.07B 4.07B 4.07B 4.07B
Cash burn (monthly) 644M 498.83M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 819.08M 634.45M n/a n/a n/a n/a
Cash remaining 3.25B 3.43B n/a n/a n/a n/a
Runway (months of cash) 5.0 6.9 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
6 May 21 Manwani Harish Common Stock Option exercise Aquire M No No 0 1,936 0 5,654
6 May 21 Manwani Harish RSU Common Stock Option exercise Dispose M No No 0 1,936 0 0
6 May 21 Whitley Richard James Common Stock Option exercise Aquire M No No 0 1,936 0 33,058
6 May 21 Whitley Richard James RSU Common Stock Option exercise Dispose M No No 0 1,936 0 4,028
6 May 21 Barton Jacqueline K Common Stock Option exercise Aquire M No No 0 1,936 0 15,676
6 May 21 Barton Jacqueline K RSU Common Stock Option exercise Dispose M No No 0 1,936 0 4,553
6 May 21 Wold Olsen Per Common Stock Option exercise Aquire M No No 0 1,936 0 102,060
6 May 21 Wold Olsen Per RSU Common Stock Option exercise Dispose M No No 0 1,936 0 0
4 May 21 Mercier Johanna Common Stock Sell Dispose S No No 66.0929 19,496 1.29M 8,068

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

77.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1519 1500 +1.3%
Opened positions 203 113 +79.6%
Closed positions 184 198 -7.1%
Increased positions 499 585 -14.7%
Reduced positions 674 623 +8.2%
13F shares
Current Prev Q Change
Total value 56.43B 60.75B -7.1%
Total shares 968.78M 961.59M +0.7%
Total puts 25.87M 25.62M +1.0%
Total calls 20.87M 19.01M +9.8%
Total put/call ratio 1.2 1.3 -8.0%
Largest owners
Shares Value Change
Capital Research Global Investors 121.67M $7.09B +3.9%
BLK Blackrock 111.18M $6.48B -5.6%
Vanguard 102.79M $5.99B +0.1%
STT State Street 55.21M $3.22B -3.1%
Capital International Investors 46.55M $2.71B -4.1%
Capital World Investors 38.53M $2.24B -2.1%
Geode Capital Management 20.08M $1.17B +0.4%
Dodge & Cox 17.11M $996.71M +35.7%
NTRS Northern Trust 15.24M $888.11M -3.8%
BK Bank Of New York Mellon 13.81M $804.37M -16.0%
Largest transactions
Shares Bought/sold Change
Norges Bank 13.17M +13.17M NEW
BLK Blackrock 111.18M -6.6M -5.6%
Capital Research Global Investors 121.67M +4.56M +3.9%
Dodge & Cox 17.11M +4.5M +35.7%
FMR 3.76M -3.95M -51.3%
BK Bank Of New York Mellon 13.81M -2.63M -16.0%
Susquehanna International 8.71M +2.58M +42.0%
AIG American International 545.7K -2.17M -79.9%
BAC Bank Of America 5.33M -2.03M -27.5%
Capital International Investors 46.55M -1.98M -4.1%

Financial report summary

  • Certain of our products subject us to additional or heightened risks.
  • Our success depends on developing and commercializing new products or expanding the indications for existing products.
  • We face challenges in accurately forecasting sales because of the difficulties in predicting demand for our products and fluctuations in purchasing patterns or wholesaler inventories.
  • We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers.
  • Our existing products are subject to reimbursement pressures from government agencies and other third parties, required rebates and other discounts on our products and other pricing pressures.
  • We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption.
  • We may face manufacturing difficulties, delays or interruptions, including at our third-party manufacturers and corporate partners.
  • Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of our products.
  • We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the health care industry.
  • We are subject to risks if significant safety issues arise for our marketed products or our product candidates.
  • Our success depends to a significant degree on our ability to obtain and defend our patents and other intellectual property rights both domestically and internationally, and to operate without infringing upon the patents or other proprietary rights of third parties.
  • We face potentially significant liability and increased expenses from litigation and government investigations relating to our products and operations.
  • Our business has been, and may in the future be, adversely affected by outbreaks of epidemic, pandemic or contagious diseases, including the recent COVID-19 outbreak.
  • We face risks associated with our global operations.
  • We depend on relationships with third parties for sales and marketing performance, technology, development, logistics and commercialization of products. Failure to maintain these relationships, poor performance by these companies or disputes with these third parties could negatively impact our business.
  • Due to the specialized and technical nature of our business, the failure to attract, develop and retain highly qualified personnel could adversely impact us.
  • We are dependent on information technology systems, infrastructure and data, which may be subject to cyberattacks, security breaches and legal claims.
  • We are subject to risks associated with engaging in business acquisitions, licensing arrangements, collaborations, options, equity investments, asset divestitures and other strategic transactions.
  • Changes in our effective income tax rate could reduce our earnings.
Management Discussion
  • Total product sales increased by 16% to $6.3 billion for the first quarter of 2021, compared to $5.5 billion for the same period in 2020, primarily due to sales of Veklury, our FDA-approved treatment for hospitalized patients with COVID-19. The first quarter of 2021 reflects growth in Cell Therapy, Trodelvy and hepatitis B virus (“HBV”)/hepatitis delta virus (“HDV”). We obtained Trodelvy through the acquisition of Immunomedics, Inc. (“Immunomedics”) in the fourth quarter of 2020. The increases were partially offset by lower HIV product sales primarily due to the continued generic competition following the October 2020 loss of exclusivity of Truvada and Atripla in the United States, in addition to higher channel inventory purchases in the first quarter of 2020 due to the COVID-19 pandemic. The decline in HCV sales was mainly driven by lower patient starts due to the continued impact of the pandemic.
Content analysis
H.S. freshman Avg
New words: abandonment, Argument, BMS, breakout, bulevirtide, Cabaret, calendar, CFCA, CODM, conditionally, constitute, content, convenience, costly, counterclaim, counterpart, Defense, delta, disaggregated, Division, Dohme, elvitegravir, enjoined, epidermal, Eshhar, factor, Fe, GAAP, German, GmbH, HDV, healthier, hepcludex, hormone, India, injectable, intervention, islatravir, job, Judicial, knowable, KR, Landgericht, liable, life, lot, Master, Mexico, misalignment, MYR, NaN, nonrecurring, NuCana, Partly, plc, preliminarily, Presidential, putative, Reciprocally, referenced, refinance, repay, rest, risky, sacituzumab, Santa, Sharp, shelter, shipment, stream, suit, tightened, TMFPA, transcriptase, translocation, tribunal, Unlimited, unresectable, urothelial, vaccination, voluntarily, waiver, website, written, Zelig
Removed: abroad, acute, add, affirming, agonist, Alameda, Allergy, antibody, appointment, ASU, attempt, banc, BPD, broader, CAFC, CEO, certiorari, children, Circuit, Clarifying, close, closed, Conference, controlling, cooperated, copay, coupon, cure, declared, declination, deliver, demonstrated, designation, dismissing, DNA, emerge, emergency, employer, en, enable, evasion, expand, extended, FASB, Forty, functional, GILTI, heading, immune, implemented, inflammatory, informed, invalidated, joined, laid, leukemia, living, managed, mantle, Mateo, methodology, modified, monoclonal, myelodysplastic, myeloid, NDA, Notwithstanding, older, opinion, originally, pause, placebo, planned, postponement, preliminary, presenting, President, prioritization, profile, rapidly, recognition, rehearing, released, reputational, request, resource, response, responsible, retaliation, retention, retrospective, retrospectively, rheumatoid, San, sclerosing, shareholder, shorten, simplify, solid, specialty, spread, strive, study, submission, supplemental, supporting, sustainable, switch, switching, targeting, Topic, transform, transformative, treated, treating, Trump, ulcerative, urgent, vacated, vesatolimod, Vice, voluntary, write